Surgical Science Sweden AB

Total Valuation

Surgical Science Sweden AB carries a market capitalization of 265.34M, placing it among publicly traded companies globally. Its enterprise value stands at 1.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Surgical Science Sweden AB currently has 51.03M shares outstanding.

Valuation Ratios

Surgical Science Sweden AB trades at a trailing price-to-earnings ratio of 21.25. The price-to-sales ratio is 1.94, and the price-to-book ratio stands at 0.43.

Enterprise Valuation

On an enterprise value basis, Surgical Science Sweden AB trades at an EV/EBITDA multiple of 10.76 and an EV/FCF ratio of 6.16. The EV/Sales ratio of 1.29 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.76 provides insight into valuation relative to core operating earnings.

Financial Position

Surgical Science Sweden AB maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Surgical Science Sweden AB posts a return on equity of 2.10 and a return on invested capital of 2.05.

Taxes

Over the trailing twelve months, Surgical Science Sweden AB has paid 32.92M in income taxes, reflecting an effective tax rate of 26.11.

Stock Price Statistics

Surgical Science Sweden AB's stock has declined approximately -47.73869% over the past 52 weeks. The 50-day moving average sits at 4.42, while the 200-day moving average is 3.58.

Income Statement

Over the trailing twelve months, Surgical Science Sweden AB generated 1.02B in revenue and converted that into 93.14M in net income, yielding earnings per share of 1.83. EBITDA reached 122.95M, while operating income came in at 122.95M.

Balance Sheet

Surgical Science Sweden AB holds 658.39M in cash and equivalents against 2.86M in total debt, resulting in a net debt position of -655.53M. Total book value stands at 4.55B, with working capital of 960.21M providing operational flexibility.

Cash Flow

Surgical Science Sweden AB produced 149.13M in operating cash flow over the past twelve months. After subtracting -65.81M in capital expenditures, free cash flow totaled 83.32M - equivalent to 1.63 per share.

Margins

Surgical Science Sweden AB operates with a gross margin of 66.50, reflecting its pricing power and cost economics. The operating margin of 12.02 and net profit margin of 9.11 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Surgical Science Sweden AB's most recent stock split took place on May 26, 2020 with a 1:5 split ratio.

Scores

Surgical Science Sweden AB posts an Altman Z-Score of 5.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.